Numab Therapeutics has successfully extended its Series C funding by raising an additional CHF 50 million, increasing the total amount raised in this round to CHF 180 million. The financing was co-led by Cormorant Asset Management, with participation from existing investors such as Forbion, HBM Healthcare Investment, and Novo Holdings. The funds will be allocated to advance multiple first-in-class and best-in-class programs into clinical development, particularly in the areas of inflammation and oncology. This extension follows a strong year for Numab, which included the acquisition of its spin-out Yellow Jersey Therapeutics by Johnson & Johnson for $1.25 billion and the initiation of clinical trials for its immuno-oncology therapeutic NM26.
In a separate development, AnaCardio has raised $19 million to support the advancement of its first-in-class drug candidate, AC01, designed to treat heart failure. This financing round attracted new international investors such as Novo Holdings and Pureos Bioventures, alongside existing investors. The funds will be used to complete the ongoing phase 1b/2a GOAL-HF1 study and prepare for a subsequent phase 2b study. AC01 is a selective oral ghrelin receptor agonist that has shown promising results in improving heart contractility without the adverse effects commonly associated with traditional inotropes.
Both companies are making significant strides in their respective fields, aiming to enhance treatment options for patients with critical health conditions.
Related topics:
